Angiogenesis

, Volume 16, Issue 1, pp 159–170

Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors

  • Jacob E. Koskimaki
  • Esak Lee
  • William Chen
  • Corban G. Rivera
  • Elena V. Rosca
  • Niranjan B. Pandey
  • Aleksander S. Popel
Original Paper

DOI: 10.1007/s10456-012-9308-7

Cite this article as:
Koskimaki, J.E., Lee, E., Chen, W. et al. Angiogenesis (2013) 16: 159. doi:10.1007/s10456-012-9308-7

Abstract

Angiogenesis is central to many physiological and pathological processes. Here we show two potent bioinformatically-identified peptides, one derived from collagen IV and translationally optimized, and one from a somatotropin domain-containing protein, synergize in angiogenesis and lymphangiogenesis assays including cell adhesion, migration and in vivo Matrigel plugs. Peptide-peptide combination therapies have recently been applied to diseases such as human immunodeficiency virus (HIV), but remain uncommon thus far in cancer, age-related macular degeneration and other angiogenesis-dependent diseases. Previous work from our group has shown that the collagen IV-derived peptide primarily binds β1 integrins, while the receptor for the somatotropin-derived peptide remains unknown. We investigate these peptides’ mechanisms of action and find both peptides affect the vascular endothelial growth factor (VEGF) pathway as well as focal adhesion kinase (FAK) by changes in phosphorylation level and total protein content. Blocking of FAK both through binding of β1 integrins and through inhibition of VEGFR2 accounts for the synergy we observe. Since resistance through activation of multiple signaling pathways is a central problem of anti-angiogenic therapies in diseases such as cancer, we suggest that peptide combinations such as these are an approach that should be considered as a means to sustain anti-angiogenic and anti-lymphangiogenic therapy and improve efficacy of treatment.

Keywords

AngiogenesisSynergyCombination therapyPeptideInhibitor

Supplementary material

10456_2012_9308_MOESM1_ESM.doc (28 kb)
Supplementary material 1 (DOC 28 kb)
10456_2012_9308_MOESM2_ESM.tif (27.9 mb)
Supplementary material 2 (TIFF 28594 kb)

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Jacob E. Koskimaki
    • 1
  • Esak Lee
    • 2
  • William Chen
    • 1
  • Corban G. Rivera
    • 1
  • Elena V. Rosca
    • 1
  • Niranjan B. Pandey
    • 1
  • Aleksander S. Popel
    • 1
    • 2
    • 3
  1. 1.Department of Biomedical Engineering, School of MedicineJohns Hopkins UniversityBaltimoreUSA
  2. 2.Department of Chemical and Biomolecular EngineeringJohns Hopkins UniversityBaltimoreUSA
  3. 3.Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, School of MedicineJohns Hopkins UniversityBaltimoreUSA